NVO•benzinga•
Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages
Summary
Novo Nordisk sues KBP Biosciences, seeking $830 million in damages over Ocedurenone, alleging data misrepresentation that led to a failed Phase 3 trial.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 19, 2025 by benzinga